JPRN-UMIN000010036招募中未知
A clinical study of pazufloxacin administered at a dose of 1,000mg twice daily in patients with sepsis due to urogenital infection - A clinical study of pazufloxacin in patients with sepsis due to urogenital infection
PO CREC net0 个研究点目标入组 100 人开始时间: 2013年2月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(Exclusion criteria) Complicated pyelonephritis with catheter detention (exclusion an indwelling catheter in the living body) Acute epididymitis with Chlamydia. Bacterial count Viable bacterial count before initiation of medication less than 104CFU/ml(medstream urine less than 105CFU/ml) Pyuria: Patients meeting any of the following criteria Prescribed equipment that uses non-centrifuged urine less than 10WBCs/ul Counting chamber method that uses noncentrifuged urine less than 10WBCs/mm3 Uinary test strip that uses nonentrifuged urine negative Microscopy of urinary sediment less than 5WBCs/hpf (Omission criteria) 1 Patients who has an anamnesis of hypersensitivity to the ingredient of this agent 2 Patients who has a critical obstacle of heaet,liver or kidney 3 Patients with the anamnesis of a spasm or epilepsy 4 Pregnant women or patients at a risk of pregnancy 5 Patients who are already improved with an antimicrobial agent before PZFX medication 6 Patients who admitted that a doctor in charge is unsuitable
研究者
相似试验
终止
4 期
A Randomized, Controlled Trial of Prulifloxacin as Switched Therapy after Intravenous Carbapenem in The Treatment of Acute Pyelonephritis Caused by Third Generation Cephalosporin Resistant Pathogens: A Pilot studyPatients with acute pyelonephritis caused by third generation cephalosporin resistant pathogens with or without bacteremia/sepsisprulifloxacin, ertapenem, pyelonephritis, extended-spectrum beta lactamaseTCTR20181202002THAI MEIJI PHARMACEUTICAL CO., LTD.30
进行中（未招募）
不适用
A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers with compensated liver disease. - Clinical pharmacology study of A-831 in Hepatitis C carriersEUCTR2007-000328-42-GBArrow Therapeutics Ltd36
尚未招募
Unknown
Effect of Phala Ghrita and Panchvalkaladi Kwath Yoni Prakshlana on VulvovagnitisCTRI/2023/08/056850Madan Mohan Malviya Government Ayurved College Udaipur
尚未招募
4 期
Study of a product containing Phtalox® for the prevention and control of PyorrheaMouthwashesDental CareGingival HyperplasiaC07465714C05116264150K056RBR-6jts634niversidade Federal de Alfenas
已完成
2 期
The effect of intravenous acetaminophen in reducing Post-operative opioid requirements after maxillofacial surgery.Maxillofacial Surgery( correction after injury).IRCT138711221674N1Vice chancellor for research, Shiraz University of Medical Sciences100